articleTop 1% cited

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Journal of Clinical Oncology · 1996 · Vol. 14(1) · pp. 7–17

J M Kirkwood✉(University of Pittsburgh Medical Center)M H StrawdermanMarc S. ErnstoffThomas J. SmithE C BordenRonald H. Blum

View via DOI Publisher page

Abstract

IFN alpha-2b prolongs the relapse-free interval and overall survival of high-risk resected melanoma patients. The increment in median disease-free survival (from 1 to 1.7 years) and overall survival (from 2.8 to 3.8 years) that results from this therapy is associated with a 42% improvement in the fraction of patients who are continuously disease-free after treatment with IFN (from 26% to 37%) in comparison to observation. IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.

Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways Immunotherapy and Immune ResponsesMedicineDiscontinuationAlpha interferonMelanomaAdjuvant therapyInternal medicineInterferon alfaToxicityAdjuvantOncology

MeSH terms

Interferon alpha-2Combined Modality TherapyDrug Administration ScheduleFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRecombinant ProteinsSkin NeoplasmsSurvival Rate

Citations

2,101

FWCI

55.06

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993